Report Type: Therapy Reports
Report Category: Respiratory
Report Subcategory: Idiopathic Pulmonary Fibrosis
Price: 2999.00
Date: January 2022

Idiopathic Pulmonary Fibrosis: Global Market Landscape till 2030 - Epidemiology, Drugs, Trials, Technology, Companies, News, Deals, Patents, Drug Sales & Forecast, Future Events, DMF, and Manufacturing

Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis is a chronic, progressive lung disease, causes scar tissue (fibrosis) to build up in the lungs, which makes the lungs unable to transport oxygen into the bloodstream effectively. 

Top 10 Companies:
Johnson & Johnson
F. Hoffmann-La Roche Ltd
Novartis AG
Merck & Co Inc
GlaxoSmithKline Plc
Sanofi
Bristol-Myers Squibb Co
AstraZeneca Plc
Amgen Inc
Gilead Sciences Inc